Eagle Pharmaceuticals Inc Announces Worldwide Licensing Agreement with Combioxin SA Corporate Call Transcript
Good morning, everyone. My name is Britney, and I will be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals CAL02 Investor Call. (Operator Instructions) As a reminder, this conference call is being recorded today, September 9, 2021.
It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.
Thank you, Britney. Welcome to Eagle Pharmaceuticals CAL02 investor event. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With us on today's call are Eagle's Chief Executive Officer, Scott Tarriff; and Chief Medical Officer, Dr. Judith Ng-Cashin; along with our guest speakers, Dr. Samareh Lajaunias, Managing Director of Combioxin SA and Dr. Andre Kalil from the University of Nebraska Medical Center. A webcast of this call can be accessed through the Investor's section of the Eagle website at eagleus.com.
Please note that we intend to take questions specific to CAL02 only on this call. Before we get started, I would like
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |